Navigation Links
Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
Date:10/6/2008

MOUNTAIN VIEW, Calif. and SEATTLE, Oct. 6 /PRNewswire/ -- Complete Genomics Inc., a newly launched, third-generation human genome sequencing company, and the Institute for Systems Biology (ISB) today announced their partnership to conduct populationwide human genome studies.

In phase one of the project, Complete Genomics will use its proprietary DNA sequencing technology to sequence five genomes from samples provided by ISB. Then, once proof-of-concept has been demonstrated, ISB and Complete Genomics plan to expand this collaboration to sequence the genomes of 100 individuals in 2009 and 2,000 individuals in 2010.

"Using Complete Genomics' human genome sequencing services to gather populationwide human genetic data will allow us to gain a more complete understanding of the genetic components and molecular processes of diseases in order to better manage, treat and prevent human disease and better understand human health," said Dr. Leroy Hood, president of ISB and member of Complete Genomics' Scientific Advisory Board.

"This collaboration demonstrates the value of our sequencing service business model and underscores our vision of using our large-scale, low-cost DNA sequencing technology to elucidate disease pathways," said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. "We are pleased to be partnering with such a renowned organization as the Institute for Systems Biology on a project that will provide the data that researchers need to develop better drugs, therapeutics and diagnostics."

About Complete Genomics

Founded in 2006, Complete Genomics is a California company that has developed a novel approach to sequencing human DNA. Complete Genomics plans to combine its proprietary third-generation DNA sequencing technology and its high-performance computing capabilities to create a human genome sequencing service that will deliver low-cost, high-quality data on an unprecedented scale. The company is currently building the world's largest human genome sequencing center. This development will allow pharmaceutical and biotechnology customers, for the first time, to conduct large-scale human genome studies that will help identify the genetic underpinnings of complex diseases and drug responses. For additional information about the company, please visit http://www.completegenomics.com.

About the Institute for Systems Biology

Founded in 2000, the Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. ISB seeks to use systems methods to unravel the complexity of human biology and identify strategies for predicting and preventing significant diseases such as cancer, diabetes and AIDS. ISB's systems approach integrates biology, computation and technological development, focusing on entire, complex biological systems rather than one gene or protein at a time. For more information about ISB, visit http://www.systemsbiology.org.


'/>"/>
SOURCE Complete Genomics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
2. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
3. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Recruitment Completed in Ofatumumab NHL Pivotal Study
5. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
8. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
9. DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties
10. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 Research and Markets has announced the ... Market Outlook: 2016-2022" report to their offering. ... The global patient safety and ... delivery, end-user, and geography. Patient safety has become ... The field has developed significantly in the last decade and is ...
(Date:3/28/2017)... , March 28, 2017 "Chemotherapy Induced Neutropenia (CIN) – ... the disease and global market trends of the Chemotherapy Induced Neutropenia ... , Europe ( France , ... Spain , UK) and Japan , ... and rest of the world (RoW). The Report covers ...
(Date:3/28/2017)...  Medeon Biodesign, Inc., a Taiwan ... announce that the Company led and successfully closed ... a San Jose, CA ... extremity applications.  The orthopedic extremity ... to procedure volume growth, lifestyle influences and favorable ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... dedicated to advancing the science and clinical practice of radiosurgery, announced today ... Registry, a multi-institutional, observational registry established to standardize data collection from patients ...
(Date:3/28/2017)... Wallingford, CT (PRWEB) , ... March 28, 2017 ... ... hemostatic devices, announces today that the University of Pittsburgh Medical Center (UPMC) will ... Central and Western Pennsylvania. , The program, developed in association with efforts by ...
(Date:3/28/2017)... VA (PRWEB) , ... March 28, 2017 , ... The ... Still, MHA, FRBMA, has begun to serve as its new executive director. Mr. Still ... the Executive Search Committee. , “Bob, as he is known to our members, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of corrosive ions found in power plant water and steam. , Chlorides and ... turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions ...
Breaking Medicine News(10 mins):